Effects of a 4-week supplementation with novel bioactives N-Trans Caffeoyltyramine (NCT) and N-Trans Feruloyltyramine (NFT) on parameters of continuous glucose monitoring in individuals with prediabetes

Autores

  • Seema Gulati
  • Anoop Misra
  • Rajneesh Tiwari
  • Michelle L. Zuelch
  • Swati Kalgaonkar

DOI:

https://doi.org/10.31989/bchd.v9i2.1921

Resumo

Background: Beyond dietary modification, bioactive compounds have emerged as modulators of glycemic regulation. Silico analysis has identified N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT) as potent modulators of hepatocyte nuclear factor 4α (HNF4α), thereby favorably regulating blood glucose metabolism.

Objective: To evaluate the effects of a proprietary dietary supplement containing novel bioactives, NCT and NFT, on parameters of continuous glucose monitoring in individuals with prediabetes.

Conclusions: Overall glycemic burden, as measured using various CGM parameters, was significantly improved in response to treatment with NCT/NFT. Select measures of insulin resistance were also improved. These findings confirm the utility of a proprietary dietary supplement containing NCT/NFT to support glycemic control in individuals with dysglycemia.

Novelty of the Study: This trial is among the first to investigate the effects of novel bioactives NCT and NFT supplementation on glycemic regulation in adults with prediabetes using CGM endpoints. Unlike prior studies relying primarily on point-in-time measures (e.g., fasting glucose or serum insulin), this study integrates both cross-sectional (fasting glucose) and continuous (continuous glucose monitoring) endpoints to enable a more comprehensive evaluationof glycemic control. This second manuscript extends the initial report by focusing specifically on continuous glucose monitoring outcomes alongside previously published findings.

Keywords: glucose regulation, continuous glucose monitoring dietary supplements, Type 2 diabetes, post-prandial glucose, N-trans-Caffeoyltyramine, N-trans-Feruloyltyramine, NCT, NFT, prediabetes, HNF4α

Publicado

2026-02-14

Edição

Seção

Research Articles